

Lipum announces the Nomination Committee for the Annual General Meeting 2025

Lipum AB (publ) ("Lipum") announces its Nomination Committee for the Annual General Meeting 2025. In accordance with the decision at the Annual General Meeting 2024, the three largest shareholders in terms of voting rights are entitled to appoint a representative to constitute the Nomination Committee for the Annual General Meeting 2025 together with the Chairman of the Board.

The three largest shareholders in terms of voting rights (considering ownership groups) as of 1 September 2024 were Flerie AB, the Crafoord foundation and Adam Dahlberg with family, and Christian von Koenigsegg with companies. The Crafoord foundation and Adam Dahlberg with family have declined to appoint a representative to the Nomination Committee and thus, the matter has been passed on to Lipum's founders, who together are the fourth largest owner.

The Nomination Committee will thus consist of the following members:

Cecilia Edström - chairman, representing Flerie AB and Christian von Koenigsegg with companies
Olle Hernell representing Lipum's founders
Ingemar Kihlström, Chairman of the Board

The shareholders who have appointed members to the Nomination Committee together represent approximately 68 percent of the voting rights of all shares in the company.

Shareholders are welcome to submit proposals and views to the Nomination Committee via email to ir@lipum.se. To ensure that proposals can be considered, these must be received in good time before the Annual General Meeting, but no later than 28 February 2025.

Contacts

Ola Sandborgh, CEO

ola.sandborgh@lipum.se

+46 72 218 80 21

Web: www.lipum.se

About Us

Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

PRESS RELEASE

26 November 2024 08:30:00 CET



Attachments

[Lipum announces the Nomination Committee for the Annual General Meeting 2025](#)